Brentuximab vedotin is a targeted medication used to treat Hodgkin’s lymphoma. It works by attaching to a specific protein found on cancer cells and delivering a substance that helps destroy these cells. It is often used when the cancer has returned after previous treatments or hasn’t responded well to other therapies.

ESHAP is a combination chemotherapy regimen that includes four different medications (etoposide, methylprednisolone, cytarabine, and cisplatin). This combination is commonly used as a salvage therapy for patients with lymphoma that has returned or hasn’t responded to initial treatment. Each medication in this combination works in a different way to kill cancer cells or stop them from growing.

The trial compares the effectiveness of using ESHAP alone versus combining it with Brentuximab vedotin in treating patients whose Hodgkin’s lymphoma has either returned or didn’t respond to previous treatments.

Hodgkin Lymphoma – A type of blood cancer that starts in the lymphatic system, specifically affecting lymphocytes (a type of white blood cell). The disease typically begins in the lymph nodes, causing them to enlarge, and can spread through the lymphatic vessels to other lymph node groups. As it progresses, the abnormal lymphocytes may spread to other organs beyond the lymphatic system. The disease commonly appears first in the lymph nodes in the upper body, such as those in the neck, chest, or underarms. Hodgkin Lymphoma is characterized by the presence of specific abnormal cells called Reed-Sternberg cells.